Status:
COMPLETED
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Lead Sponsor:
Pfizer
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
15-99 years
Brief Summary
The objective of this investigation is to determine the following items in all patients receiving Torisel for a certain period after marketing: 1. Confirmation of efficacy and safety for medical prac...
Detailed Description
Implemented as a Drug Use Investigation by Central Registration System
Eligibility Criteria
Inclusion
- Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma).
Exclusion
- Patients not administered Torisel.
- Patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.
Key Trial Info
Start Date :
August 24 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2018
Estimated Enrollment :
1050 Patients enrolled
Trial Details
Trial ID
NCT01210482
Start Date
August 24 2010
End Date
May 31 2018
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kyusyu University Hospital
Fukuoka, Fukuoka PREF, Japan